Compare 10X Genomics Inc (TXG) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? 10X Genomics Inc trades at $79.14 (market cap $10.07B), while Vanguard Total Stock Market Index Fund ETF trades at $381 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 228.4× 10X Genomics Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| TXG | VTI | |
|---|---|---|
Market Cap | $10.07B | $2.30T |
Volume | 5,657,286 | 2,982,924 |
Sector | Health | — |
52-Week High | $97.74 | $384.30 |
52-Week Low | $11.48 | $311.68 |
Typical Hold Time | 92 Days | 131 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
VTI trades at $381.03, down 0.39% on the day, with bullish technical signals from moving averages. The ETF maintains broad exposure to the entire U.S. equity market with over 3,500 holdings. Recent news highlights strong long-term performance potential, with $500 monthly investments since 2001 growing to approximately $876,000 according to The Motley Fool (2026-10-01).
VTI offers diversified U.S. stock market exposure with low expense ratios, making it suitable for long-term investors. Key risks include concentration in top holdings and market volatility. Analyst sentiment remains positive for buy-and-hold strategies, though current RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
